Tokyo, Nov. 23 -- UMIN Clinical Trials Registry (UMIN-CTR) received information related to the study (UMIN000059854) titled 'Efficacy and Safety of ATP Citrate Lyase Inhibitors' on Nov. 22.
Study Type:
Interventional
Study Design:
Basic Design - Single arm
Randomization - Non-randomized
Blinding - Open -no one is blinded
Control - Uncontrolled
Primary Sponsor:
Institute - Sekino Hospital
Condition:
Condition - refractory dyslipidemia
Classification by malignancy - Others
Genomic information - NO
Objective:
Narrative objectives1 - To evaluate the safety and efficacy of ATP citrate lyase inhibitors.
Basic objectives2 - Safety,Efficacy
Intervention:
Interventions/Control_1 - Patients with treatment-resistant dyslipidemia will be administered 180 mg of an ATP citrate lyase inhibitor daily and observed for 12 months.
Eligibility:
Age-lower limit - 20
years-old
=
Gender - Male and Female
Key inclusion criteria - refractory dyslipidemia
Key exclusion criteria - Doctor's decision not to register to this regimen
Target Size - 10
Recruitment Status:
Recruitment status - Enrolling by invitation
Date of protocol fixation - 2025 Year 09 Month 07 Day
Date of IRB - 2025 Year 10 Month 10 Day
Anticipated trial start date - 2025 Year 11 Month 21 Day
Last follow-up date - 2028 Year 12 Month 31 Day
To know more, visit https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000068449
Disclaimer: Curated by HT Syndication.
